These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8450782)

  • 1. Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
    Stewart GO; Stein GR; Davis TM; Findlater P
    Med J Aust; 1993 Feb; 158(3):167-9. PubMed ID: 8450782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.
    Willey KA; Molyneaux LM; Yue DK
    Diabet Med; 1994; 11(7):701-4. PubMed ID: 7955998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
    Willey KA; Molyneaux LM; Overland JE; Yue DK
    Diabet Med; 1992 May; 9(4):341-3. PubMed ID: 1600704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M; Luft D; Blomberg I; Schmülling RM
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
    Roger P; Auclair J; Drain P
    J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine in the treatment of obese type 2 diabetic patients.
    O'Kane M; Wiles PG; Wales JK
    Diabet Med; 1994; 11(1):105-10. PubMed ID: 8181239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects.
    Glaser B; Raveh Y; Norynberg C; Berry E; Lavielle R; Nathan C; Cerasi E
    Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups.
    van der Merwe MT; Wing JR; Celgow LH; Gray IP; Lönn L; Joffe BI; Lönnroth PN
    Int J Obes Relat Metab Disord; 1996 Aug; 20(8):768-76. PubMed ID: 8856402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.